Success Metrics

Clinical Success Rate

25.0%

Based on 1 completed trials

Completion Rate

25%(1/4)

Active Trials

0(0%)

Results Posted

100%(1 trials)

Terminated

3(75%)

Phase Distribution

Ph phase_2

25%

Ph phase_3

25%

Ph phase_4

25%

Ph not_applicable

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 2Efficacy & side effects

1(25.0%)

Phase 3Large-scale testing

1(25.0%)

Phase 4Post-market surveillance

1(25.0%)

N/ANon-phased studies

1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(3)

Detailed Status

Terminated3

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

25.0%

Most Advanced

Phase 4

Trials by Phase

Phase 21 (25.0%)

Phase 31 (25.0%)

Phase 41 (25.0%)

N/A1 (25.0%)

Trials by Status

completed125%

terminated375%

Recent Activity

0 active trials

Showing 4 of 4

terminatedphase_2

A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)

NCT02343549

terminatednot_applicable

Clinical Trials (4)

Showing 4 of 4 trials

NCT02343549Phase 2

A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)

Terminated

NCT01954576Not Applicable

NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme

Terminated

NCT01756729Phase 4

Post-approval Study of NovoTTF-100A in Recurrent GBM Patients

Terminated

NCT00379470Phase 3

Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)

Completed

All 4 trials loaded

Drug Details

Intervention Type: DEVICE
Total Trials: 4